What is Leerink Partnrs’ Forecast for UTHR FY2024 Earnings?

United Therapeutics Co. (NASDAQ:UTHR) – Equities research analysts at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects that the biotechnology company will earn $25.09 per share for the year, down from their previous estimate of $25.94. The consensus estimate for United Therapeutics’ current full-year earnings is $25.21 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q1 2025 earnings at $6.95 EPS, Q2 2025 earnings at $7.31 EPS, Q3 2025 earnings at $7.81 EPS, FY2025 earnings at $29.77 EPS, FY2026 earnings at $31.02 EPS, FY2027 earnings at $30.53 EPS and FY2028 earnings at $32.83 EPS.

UTHR has been the topic of a number of other research reports. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. Argus boosted their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH raised their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Oppenheimer increased their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $382.08.

United Therapeutics Trading Up 2.2 %

Shares of UTHR stock opened at $353.31 on Wednesday. The firm’s 50 day moving average is $362.06 and its 200 day moving average is $358.24. The stock has a market capitalization of $15.78 billion, a P/E ratio of 15.52, a PEG ratio of 0.92 and a beta of 0.57. United Therapeutics has a 12 month low of $210.64 and a 12 month high of $417.82.

Insider Transactions at United Therapeutics

In related news, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares in the company, valued at $1,885,134.22. The trade was a 83.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Nilda Mesa sold 255 shares of the stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 121,864 shares of company stock worth $44,516,965. 11.90% of the stock is currently owned by insiders.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. bought a new stake in United Therapeutics in the fourth quarter worth $25,000. Brooklyn Investment Group bought a new position in United Therapeutics in the 3rd quarter worth about $33,000. Millstone Evans Group LLC bought a new position in United Therapeutics in the 4th quarter worth about $67,000. Capital Performance Advisors LLP purchased a new stake in United Therapeutics during the 3rd quarter valued at about $82,000. Finally, MassMutual Private Wealth & Trust FSB increased its stake in United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 58 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.